NCT05824338View on ClinicalTrials.gov

Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Anesthesia, SpinalNeurosurgeryRopivacaineBupivacaine
Interventions
DRUG

Spinal anesthesia for lumbar surgery: ropivacaine

The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally

DRUG

Spinal anesthesia for lumbar surgery: bupivacaine

The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.

DRUG

General anesthesia for lumbar surgery

Patient will be intubated and ventilated under general anesthesia.

Trial Locations (2)

V3L 3W7

NOT_YET_RECRUITING

Royal Columbian Hospital, New Westminster

V3H 3W9

RECRUITING

Eagle Ridge Hospital, Port Moody

Sponsors

Lead Sponsor

Fraser Health
All Listed Sponsors
lead

Fraser Health

OTHER

NCT05824338 - Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery | Biotech Hunter | Biotech Hunter